Novartis AG (NOVN) Given a CHF 83.50 Price Target at Deutsche Bank AG
A number of other brokerages have also commented on NOVN. UBS AG set a CHF 78 price objective on Novartis AG and gave the company a neutral rating in a report on Monday, August 28th. Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on Novartis AG and gave the company a neutral rating in a report on Tuesday, August 8th. Baader Bank set a CHF 90 price objective on Novartis AG and gave the company a buy rating in a report on Friday, August 4th. Morgan Stanley set a CHF 88 price objective on Novartis AG and gave the company a buy rating in a report on Wednesday, July 26th. Finally, Jefferies Group LLC set a CHF 97 target price on Novartis AG and gave the company a buy rating in a report on Monday, July 24th. Two analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of CHF 86.10.
Novartis AG (VTX NOVN) opened at CHF 81.65 on Wednesday. Novartis AG has a fifty-two week low of CHF 67.80 and a fifty-two week high of CHF 85.40.
WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/novartis-ag-novn-given-a-chf-83-50-price-target-at-deutsche-bank-ag/1697071.html.
About Novartis AG
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.